AACR Blockbuster: Safety and efficacy evaluation of first-line treatment with anti-TTX-030 combined with chemoimmunotherapy in patients with locally advanced or metastatic gastric/GEJ cancer

The exogenous ATPase CD39 is the rate-limiting enzyme in the adenosine pathway and plays an important role in immune regulation

The exogenous ATPase CD39 is the rate-limiting enzyme in the adenosine pathway and plays an important role in immune regulation

The addition of nivolumab to chemotherapy has recently become the standard of care for first-line (1L) treatment of locally advanced or metastatic (LA/M) gastric cancer , but further improvements are needed

RESULTS: Forty-four patients were enrolled, the median age [range] was 61 [30-81] years, 41% were female, and 57% were Asian

RESULTS: Forty-four patients were enrolled, the median age [range] was 61 [30-81] years, 41% were female, and 57% were Asian

Of the 38 patients evaluable for efficacy, 23 had a partial response or better best response (partial response: n=21; complete response: n=2; overall response rate=61%), and 12 patients Stable disease occurred, and 3 patients had disease progression

Preliminary results show that the combination of TTX-030, buccalizumab, and FOLFOX as 1L for LA/M gastric/GEJ cancer exhibits good efficacy and a manageable safety profile regardless of CPS status, with no evidence Indicates excessive toxicity

source:

source:

https://#!/10517/presentation/20157

https://#!/10517/presentation/20157 https://#!/10517/presentation/20157

Leave a comment here